Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase vs Allopurinol for Hyperuricemia in Cancer
NCT00230178Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2004
- Primary completion
- Dec 2007
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rasburicase in hyperuricemia, tumor lysis syndrome (TLS), sponsored by Sanofi. Started Apr 2004; status: completed.
02
Drugs
rasburicase
03
Conditions
hyperuricemiatumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT00230178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230178.